Zhittya Genesis Medicine

Executive Summary

Zhittya Genesis Medicine (ZGM) is a private US regenerative medicine company headquartered in Las Vegas, founded in 2017. The company is pioneering innovative clinical trials targeting major chronic diseases, including Parkinson's disease, heart disease, and type 2 diabetes, using cutting-edge regenerative therapies. With FDA-authorized trials underway, ZGM aims to offer new hope to patients through treatments that address disease root causes rather than just symptoms. The company's approach leverages biologic mechanisms to repair or replace damaged tissues, potentially altering disease progression. While the pipeline is still early-stage, ZGM's focus on multiple large-market indications and its regulatory engagement suggest a strategic effort to validate its platform across diverse therapeutic areas. Given the breadth of its ambitions and the nascent stage of development, the company faces significant technical and regulatory risks common to regenerative medicine. Nonetheless, if successful, ZGM could capture substantial value in the neurodegenerative, cardiovascular, and metabolic disease markets. The company's profile remains lean with limited public disclosure, making it a speculative but potentially high-reward opportunity for investors seeking exposure to early-stage biotech innovation.

Upcoming Catalysts (preview)

• Q4 2026Interim data readout from Phase I/II Parkinson's disease trial40% success
• Q2 2027FDA acceptance of Investigational New Drug (IND) application for heart disease program50% success
• Q3 2026Publication of preclinical results in type 2 diabetes model60% success